Man Group
KROS icon

Man Group’s Keros Therapeutics KROS Stock Holding History

Man Group’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.66M Sell
155,541
-83,077
-35% -$925K ﹤0.01% 1643
2026
Q1 		$2.63M Buy
238,618
+48,411
+25% +$748K ﹤0.01% 1449
2025
Q4 		$3.87M Sell
190,207
-2,647
-1% -$46.4K 0.01% 1190
2025
Q3 		$3.05M Buy
192,854
+71,309
+59% +$1.05M 0.01% 1260
2025
Q2 		$1.62M Buy
121,545
+87,532
+257% +$1.18M ﹤0.01% 1485
2025
Q1 		$347K Buy
+34,013
New +$395K ﹤0.01% 1899

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Man Group's KROS Position: Q2 2026 in Review

Man Group reduced its Keros Therapeutics (KROS) stake by 35% in Q2 2026, selling an estimated $925K and leaving 155,541 shares worth $1.66M. The position accounts for ﹤0.01% of the portfolio, ranked #1643.

Man Group first reported a position in KROS in Q1 2025 and has held it in 6 quarters since. The position peaked at $3.87M in Q4 2025. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Man Group held 155,541 shares of Keros Therapeutics worth $1.66M as of Q2 2026.
  • Man Group sold 83,077 Keros Therapeutics shares in Q2 2026, an estimated $925K.
  • Keros Therapeutics made up ﹤0.01% of Man Group's portfolio in Q2 2026, its #1643 holding.
  • Man Group first reported a position in Keros Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Man Group's Keros Therapeutics position peaked at $3.87M in Q4 2025.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.